{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:36:08Z","timestamp":1777581368624,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111337","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:19:36Z","timestamp":1701958776000},"page":"111337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-0265","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2023.111337_b0005","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/cncr.32789","article-title":"Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990\u20132017","volume":"126","author":"Liu","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2023.111337_b0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/jrms.JRMS_1017_18","article-title":"Predictors of 5 year survival rate in hepatocellular carcinoma patients","volume":"24","author":"Sarveazad","year":"2019","journal-title":"J Res Med Sci."},{"issue":"17","key":"10.1016\/j.intimp.2023.111337_b0015","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2023.111337_b0020","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.111337_b0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13543776.2022.2045276","article-title":"Small molecule inhibitors of programmed cell death ligand 1 (PD-L1): A Patent Review (2019\u20132021)","volume":"32","author":"Deng","year":"2022","journal-title":"Expert Opin Ther Pat."},{"key":"10.1016\/j.intimp.2023.111337_b0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol."},{"issue":"20","key":"10.1016\/j.intimp.2023.111337_b0035","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0040","first-page":"1003","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label","volume":"27","author":"Xu","year":"2021","journal-title":"Phase II Trial. Clin Cancer Res."},{"key":"10.1016\/j.intimp.2023.111337_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109437","article-title":"Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"Biomed Pharmacother."},{"issue":"17","key":"10.1016\/j.intimp.2023.111337_b0050","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.intimp.2023.111337_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107796","article-title":"Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis","volume":"96","author":"Balibegloo","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.111337_b0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2023.111337_b0070","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4158\/EP-2018-0114","article-title":"Latent Adrenal Insufficiency: Concept, Clues to Detection, and Diagnosis","volume":"24","author":"Yamamoto","year":"2018","journal-title":"Endocr Pract."},{"issue":"12","key":"10.1016\/j.intimp.2023.111337_b0075","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.111337_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"11","key":"10.1016\/j.intimp.2023.111337_b0085","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111337_b0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0095","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.111337_b0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2019-0674","article-title":"Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma","volume":"25","author":"Suo","year":"2020","journal-title":"Oncologist."},{"key":"10.1016\/j.intimp.2023.111337_b0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2023.111337_b0110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111337_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","volume":"11","author":"Ng","year":"2022","journal-title":"Liver Cancer."},{"key":"10.1016\/j.intimp.2023.111337_b0120","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-023-05093-3","article-title":"Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis","author":"Cai","year":"2023","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.intimp.2023.111337_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704475","article-title":"The prognostic significance of the continuous administration of anti-PD-1 antibody via continuation or rechallenge after the occurrence of immune-related adverse events","volume":"11","author":"Fujisaki","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.111337_b0130","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.intimp.2023.111337_b0135","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J Hepatol."},{"issue":"10088","key":"10.1016\/j.intimp.2023.111337_b0140","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2023.111337_b0145","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111337_b0150","first-page":"193","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind","volume":"38","author":"Finn","year":"2020","journal-title":"Phase III Trial. J Clin Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.111337_b0155","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111337_b0160","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9203","key":"10.1016\/j.intimp.2023.111337_b0165","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(99)06290-X","article-title":"Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment","volume":"355","author":"Henzen","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2023.111337_b0170","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.2019-00153","article-title":"Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England","volume":"104","author":"Mebrahtu","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0175","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2012-4085","article-title":"Clinical review: kinase inhibitors: adverse effects related to the endocrine system","volume":"98","author":"Lodish","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"10.1016\/j.intimp.2023.111337_b0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/1759-7714.14761","article-title":"Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer","volume":"14","author":"Kurokawa","year":"2023","journal-title":"Thorac Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2023.111337_b0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12032-020-01357-x","article-title":"Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer","volume":"37","author":"Ida","year":"2020","journal-title":"Med Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2023.111337_b0195","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.111337_b0200","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.intimp.2023.111337_b0205","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2023.111337_b0210","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1634\/theoncologist.2019-0637","article-title":"Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with food and drug administration-approved indications for immunotherapy","volume":"25","author":"Das","year":"2020","journal-title":"Oncologist."},{"issue":"1","key":"10.1016\/j.intimp.2023.111337_b0215","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.cllc.2018.09.005","article-title":"Efficacy of nivolumab and pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: A retrospective multicenter analysis","volume":"20","author":"Ksienski","year":"2019","journal-title":"Clin Lung Cancer."},{"issue":"9","key":"10.1016\/j.intimp.2023.111337_b0220","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111337_b0225","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.111337_b0230","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J Gastroenterol."},{"issue":"10126","key":"10.1016\/j.intimp.2023.111337_b0235","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:12:32Z","timestamp":1761588752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923016648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":47,"alternative-id":["S1567576923016648"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111337","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111337"}}